Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.
NCT01837927 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL
Last updated 2016-08-22
Summary
This study will assess the Efficacy of NVA237 (50 μg o.d) using tiotropium (5μg μg o.d) as active control in COPD patients.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- DRUG
-
NVA237
Once daily for 52 weeks
- DRUG
-
Tiotropium Respimat®
Once daily for 52 weeks
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-04-30
- Primary Completion
- 2016-04-30
- Completion
- 2016-04-30
More Related Trials
-
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
NCT04223843 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01490125 ·Status: COMPLETED ·Phase: PHASE3
-
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00929110 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01529632 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD
NCT01959516 ·Status: COMPLETED ·Phase: PHASE4
-
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
NCT00239473 ·Status: COMPLETED ·Phase: PHASE3
-
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
NCT01431287 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation
NCT01610037 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01574651 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
NCT02242279 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
NCT02603393 ·Status: COMPLETED ·Phase: PHASE4
-
Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT02172794 ·Status: COMPLETED ·Phase: PHASE3
-
Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD
NCT02683109 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01119950 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01372410 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00856193 ·Status: COMPLETED ·Phase: PHASE2
-
12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales
NCT02172378 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
NCT02853123 ·Status: COMPLETED ·Phase: PHASE4
-
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
NCT00696020 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01285492 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease
NCT00279019 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02238119 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD
NCT00274040 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD
NCT00239460 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.
NCT01703845 ·Status: COMPLETED ·Phase: PHASE1